盐酸氨溴索结合盐酸丙卡特罗治疗小儿肺炎的效果分析

Effect of Ambroxol Hydrochloride Combined with Procaterol Hydrochloride in the Treatment of Infantile Pneumonia

目的针对小儿肺炎使用盐酸丙卡特罗联合盐酸氨溴索治疗的临床效果展开分析与探讨。方法方便选取2022年1月—2023年1月期间政和县医院收治小儿肺炎患儿76例为研究对象,根据随机抽签原则划分为对照组38例和研究组38例,分别应用盐酸丙卡特罗治疗、盐酸氨溴索+盐酸丙卡特罗治疗,针对两组炎症因子变化情况、临床症状改善时间、临床疗效、用药安全性展开比较与研究。结果治疗后,研究组降钙素原、白介素-6、C反应蛋白测定结果均明显低于对照组,差异有统计学意义(P<0.05)。研究组喘息、咳嗽、发热、肺部啰音、肺部阴影改善时间均短于对照组,差异有统计学意义(P<0.05)。研究组临床总疗效为97.37%,高于对照组的78.95%,差异有统计学意义(χ^(2)=4.537,P<0.05)。研究组用药不良反应发生率为7.89%,与对照组的5.26%比较,差异无统计学意义(χ^(2)=0.000,P>0.05)。结论通过使用盐酸氨溴索与盐酸丙卡特罗联合的方式对小儿肺炎患儿实施临床治疗,可以显著降低炎症因子指标,缩短症状改善时间,临床疗效突出,增加治疗药物没有明显增加不良反应发生率,因此用药安全性良好。

Objective To analyze and discuss the clinical effect of procaterol hydrochloride combined with ambroxol hydrochloride for pediatric pneumonia.Methods A total of 76 children with pneumonia admitted to Zhenghe County Hospital from January 2022 to January 2023 were conveniently selected as the study objects,and they were divided into control group(38 cases)and study group(38 cases)according to the principle of random drawing.Procatterol hydrochloride,ambroxol hydrochloride and procatterol hydrochloride were respectively treated.The changes of inflammatory factors,improvement time of clinical symptoms,clinical efficacy and drug safety of the two groups were compared and studied.Results After treatment,the results of procalcitonin,interleukin-6 and C-reactive protein in the study group were significantly lower than those in the control group,and the differences were statistically significant(P<0.05).The improvement time of wheezing,cough,fever,pulmonary rales and pulmonary shadow in the study group were shorter than that in the control group,and the differences were statistically significant(P<0.05).The total clinical efficacy of the study group was 97.37%,which was higher than that of the control group(78.95%),and the difference was statistically significant(χ^(2)=4.537,P<0.05).The incidence of adverse drug reactions in the study group was 7.89%compared with 5.26%in the control group,and the difference was not statistically significant(χ^(2)=0.000,P>0.05).Conclusion The combination of ambroxol hydrochloride and procaterol hydrochloride for the clinical treatment of children with pneumonia can significantly reduce inflammatory factor indicators and shorten the time for symptom improvement.The clinical effect is outstanding,and the incidence of adverse reactions is not significantly increased by increasing therapeutic drugs,so the drug is safe.